Sun Pharma launches Ilumya (Tildrakizumab) in India, expanding its specialty medicines portfolio and bringing advanced ...
Sun Pharmaceutical Industries on Monday said it has launched its global innovative drug ILUMYA in India for the treatment of ...
Sun Pharma's managing director, Kirti Ganorkar, said Ilumya is already available in 35 countries and has consistently ...
Sun Pharmaceutical Industries has announced the launch of its global innovative drug, Ilumya (tildrakizumab) in India for ...
Innovent Biologics has picked up approval in China for Pecondle, its anti-IL-23p19 antibody, as a treatment for ...
Researchers in China report that global incidence rates of psoriasis rose slightly from 1990 to 2021 and are projected to ...
Despite challenges such as high costs and access barriers, the demand for effective, tailored therapies continues to rise, transforming the psoriasis treatment landscapeDublin, Nov. 26, 2025 (GLOBE ...
Psoriasis is a chronic, immune-mediated skin condition. It causes red, scaly, itchy, often inflamed patches. Because the ...
Sun Pharmaceutical Industries announced the launch of its global innovative drug, ILUMYA (Tildrakizumab) in India for moderate-to-severe plaque psoriasis. A novel biologic treatment, ILUMYA has been ...
An expert panel calls the requirement for tuberculosis testing before prescribing IL-17 and IL-23 biologics for psoriasis an ...
Sun Pharma introduces Ilumya in India for treatment of moderate-to-severe plaque psoriasis: Our Bureau, Mumbai Tuesday, December 2, 2025, 14:45 Hrs [IST] Sun Pharma has announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback